354 related articles for article (PubMed ID: 27843789)
1. Real world evidence: An Indian perspective.
Dang A; Vallish BN
Perspect Clin Res; 2016; 7(4):156-160. PubMed ID: 27843789
[TBL] [Abstract][Full Text] [Related]
2. The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia.
Webster J; Smith BD
Clin Ther; 2019 Feb; 41(2):336-349. PubMed ID: 30709609
[TBL] [Abstract][Full Text] [Related]
3. Payer perceptions of the use of real-world evidence in oncology-based decision making.
Brixner D; Biskupiak J; Oderda G; Burgoyne D; Malone DC; Arondekar B; Niyazov A
J Manag Care Spec Pharm; 2021 Aug; 27(8):1096-1105. PubMed ID: 34337998
[No Abstract] [Full Text] [Related]
4. Conducting real-world evidence studies in India.
Bhatt A
Perspect Clin Res; 2019; 10(2):51-56. PubMed ID: 31008069
[TBL] [Abstract][Full Text] [Related]
5. Contemporary Databases in Real-world Studies Regarding the Diverse Health Care Systems of India, Thailand, and Taiwan: Protocol for a Scoping Review.
Shau WY; Setia S; Shinde SP; Santoso H; Furtner D
JMIR Res Protoc; 2022 Dec; 11(12):e43741. PubMed ID: 36512386
[TBL] [Abstract][Full Text] [Related]
6. Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward.
Lou J; Kc S; Toh KY; Dabak S; Adler A; Ahn J; Bayani DBS; Chan K; Choiphel D; Chua B; Genuino AJ; Guerrero AM; Kearney B; Lin LW; Liu Y; Nakamura R; Pearce F; Prinja S; Pwu RF; Shafie AA; Sui B; Suwantika A; Teerawattananon Y; Tunis S; Wu HM; Zalcberg J; Zhao K; Isaranuwatchai W; Wee HL
Int J Technol Assess Health Care; 2020 Oct; 36(5):474-480. PubMed ID: 32928330
[TBL] [Abstract][Full Text] [Related]
7. Real-World Evidence: A Primer.
Dang A
Pharmaceut Med; 2023 Jan; 37(1):25-36. PubMed ID: 36604368
[TBL] [Abstract][Full Text] [Related]
8. Impact of Real-World Data on Market Authorization, Reimbursement Decision & Price Negotiation.
Pulini AA; Caetano GM; Clautiaux H; Vergeron L; Pitts PJ; Katz G
Ther Innov Regul Sci; 2021 Jan; 55(1):228-238. PubMed ID: 32857313
[TBL] [Abstract][Full Text] [Related]
9. Trial designs using real-world data: The changing landscape of the regulatory approval process.
Baumfeld Andre E; Reynolds R; Caubel P; Azoulay L; Dreyer NA
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1201-1212. PubMed ID: 31823482
[TBL] [Abstract][Full Text] [Related]
10. Replication of Randomized, Controlled Trials Using Real-World Data: What Could Go Wrong?
Thompson D
Value Health; 2021 Jan; 24(1):112-115. PubMed ID: 33431143
[TBL] [Abstract][Full Text] [Related]
11. Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.
Orsini LS; Berger M; Crown W; Daniel G; Eichler HG; Goettsch W; Graff J; Guerino J; Jonsson P; Lederer NM; Monz B; Mullins CD; Schneeweiss S; Brunt DV; Wang SV; Willke RJ
Value Health; 2020 Sep; 23(9):1128-1136. PubMed ID: 32940229
[TBL] [Abstract][Full Text] [Related]
12. Real-world evidence: perspectives on challenges, value, and alignment of regulatory and national health technology assessment data collection requirements.
Sievers H; Joos A; Hiligsmann M
Int J Technol Assess Health Care; 2021 Feb; 37():e40. PubMed ID: 33622423
[TBL] [Abstract][Full Text] [Related]
13. Current Status, Challenges, and Future Perspectives of Real-World Data and Real-World Evidence in Japan.
Hiramatsu K; Barrett A; Miyata Y;
Drugs Real World Outcomes; 2021 Dec; 8(4):459-480. PubMed ID: 34148219
[TBL] [Abstract][Full Text] [Related]
14. Real-world evidence and product development: Opportunities, challenges and risk mitigation.
Naidoo P; Bouharati C; Rambiritch V; Jose N; Karamchand S; Chilton R; Leisegang R
Wien Klin Wochenschr; 2021 Aug; 133(15-16):840-846. PubMed ID: 33837463
[TBL] [Abstract][Full Text] [Related]
15. Reality check: Real-world evidence to support therapeutic development in hematologic malignancies.
Derman BA; Belli AJ; Battiwalla M; Hamadani M; Kansagra A; Lazarus HM; Wang CK
Blood Rev; 2022 May; 53():100913. PubMed ID: 35272867
[TBL] [Abstract][Full Text] [Related]
16. Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration.
Chan K; Nam S; Evans B; de Oliveira C; Chambers A; Gavura S; Hoch J; Mercer RE; Dai WF; Beca J; Tadrous M; Isaranuwatchai W
BMJ Open; 2020 Jan; 10(1):e032884. PubMed ID: 31915169
[TBL] [Abstract][Full Text] [Related]
17. Expert survey on real-world data utilization and real-world evidence generation for regulatory decision-making in drug lifecycle in Korea.
Lee H; Ahn HS; Kwon S; Kang HY; Han E
Clin Transl Sci; 2024 Apr; 17(4):e13801. PubMed ID: 38629484
[TBL] [Abstract][Full Text] [Related]
18. Harnessing the Potential of Real-World Evidence in the Treatment of Colorectal Cancer: Where Do We Stand?
van Nassau SCMW; Bol GM; van der Baan FH; Roodhart JML; Vink GR; Punt CJA; May AM; Koopman M; Derksen JWG
Curr Treat Options Oncol; 2024 Apr; 25(4):405-426. PubMed ID: 38367182
[TBL] [Abstract][Full Text] [Related]
19. Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions.
Wu J; Wang C; Toh S; Pisa FE; Bauer L
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1213-1218. PubMed ID: 32003065
[TBL] [Abstract][Full Text] [Related]
20. Use of Real-World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design.
Dagenais S; Russo L; Madsen A; Webster J; Becnel L
Clin Pharmacol Ther; 2022 Jan; 111(1):77-89. PubMed ID: 34839524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
